十分之一的临床药物试验存在主要终点不一致:一项起始队列研究的结果
该起始队列研究分析了荷兰机构审查委员会2007年审查的所有已发表临床药物试验,比较试验方案与发表论文在关键报告方面的差异。334项已发表试验中32项(9.6%)主要终点存在方案与发表不一致,随机对照试验亚组204项中12项(5.9%)不一致。作者认为仍需提高报告完整性,尤其针对研究者发起的试验和非随机对照试验。
要点
- 334项已发表药物试验中32项(9.6%)主要终点存在方案与发表不一致。
- 研究者发起且有或无企业共同资助的试验主要终点不一致风险高于企业资助试验。
- 作者认为应提高报告完整性,试验发表时方案应同时公开。
核心结论
- 仍需提高报告完整性,尤其是研究者发起的试验和非随机对照试验。
- 为消除未披露的不一致,试验方案应在试验发表时同时公开于公共领域。
研究设计与样本
- 起始队列研究,分析荷兰机构审查委员会2007年审查的所有已发表临床药物试验。
- 共纳入334项已发表试验,其中随机对照试验204项。
- 比较试验方案与发表论文在关键报告方面的差异,并计算风险比(RR)及95%置信区间(CI)评估试验特征与主要终点不一致的关联。
主要发现
- 334项已发表试验中32项(9.6%)主要终点存在方案与发表不一致。
- 随机对照试验亚组204项中12项(5.9%)主要终点存在不一致。
- 研究者发起且有企业共同资助的试验较企业资助试验主要终点不一致风险升高(RR 3.7;95% CI 1.4-9.9)。
- 研究者发起且无企业资助的试验较企业资助试验主要终点不一致风险升高(RR 4.4;95% CI 2.0-9.5)。
- 其他与主要终点不一致显著相关的因素包括:其他分期试验(对比1期;RR 4.6;95% CI 1.1-19.3)、多中心试验在欧盟以外开展(对比单中心;RR 0.2;95% CI 0.1-0.6)、未前瞻性注册的试验(RR 3.3;95% CI 1.5-7.5)、非随机对照试验(对比优效性随机对照试验;RR 2.4;95% CI 1.2-4.8),以及随机对照试验中交叉设计对比平行组设计(RR 3.7;95% CI 1.1-12.3)。
临床怎么用
- 作者认为仍需提高报告完整性,尤其是研究者发起的试验和非随机对照试验。
- 作者认为为消除未披露的不一致,试验方案应在试验发表时同时公开于公共领域。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify the occurrence and determinants of protocol-publication discrepancies in clinical drug trials. STUDY DESIGN AND SETTING: All published clinical drug trials reviewed by the Dutch institutional review boards in 2007 were analyzed. Discrepancies between trial protocols and publications were measured among key reporting aspects. We evaluated the association of trial characteristics with discrepancies in primary endpoints by calculating the risk ratio (RR) and 95% confidence interval (CI). RESULTS: Of the 334 published trials, 32 (9.6%) had a protocol/publication discrepancy in the primary endpoints. Among the subgroup of randomized controlled trials (RCTs; N = 204), 12 (5.9%) had a discrepancy in the primary endpoint. Investigator-initiated trials with and without industry (co-) funding were associated with having discrepancies in the primary endpoints compared with industry-sponsored trials (RR 3.7; 95% CI 1.4-9.9 and RR 4.4; 95% CI 2.0-9.5, respectively). Furthermore, other than phase 1-4 trials (vs. phase 1; RR 4.6; 95% CI 1.1-19.3), multicenter trials were also conducted outside the European Union (vs. single center; RR 0.2; 95% CI 0.1-0.6), not prospectively registered trials (RR 3.3; 95% CI 1.5-7.5), non-RCTs (vs. superiority RCT; RR 2.4; 95% CI 1.2-4.8) and, among the RCTs, crossover compared with a parallel group design (RR 3.7; 95% CI 1.1-12.3) were significantly associated with having discrepancies in the primary endpoints. CONCLUSIONS: Improvement in completeness of reporting is still needed, especially among investigator-initiated trials and non-RCTs. To eliminate undisclosed discrepancies, trial protocols should be available in the public domain at the same time when the trial is published.
引用
- van den Bogert CA, Souverein PC, Brekelmans CTM, et al. Primary endpoint discrepancies were found in one in ten clinical drug trials. Results of an inception cohort study. J Clin Epidemiol. 2017. PMID: 28535887. doi:10.1016/j.jclinepi.2017.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。